Pieter E. Postmus
YOU?
Author Swipe
View article: Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands
Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands Open
Short-term mortality rates following curative intent radiotherapy for lung cancer in the Netherlands are low and independent of facility volume. It was demonstrated that 90-day mortality is an arguable indicator to monitor radiotherapy qua…
View article: Nintedanib for the treatment of symptomatic radiation pneumonitis. A Case Report
Nintedanib for the treatment of symptomatic radiation pneumonitis. A Case Report Open
View article: 181P Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands
181P Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands Open
The 90-day mortality following lung cancer treatment is often included in sets of performance indicators to monitor quality of care. The aim of the current study was to investigate te 90-day mortality rate following curative intent radioth…
View article: Supplementary Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i>
Supplementary Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i> Open
Supplementary Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma In situ
View article: Supplementary Table 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Supplementary Table 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
PDF File - 77K, Supplementary data showing measurements in evaluable tumors.
View article: Supplementary Figure 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Supplementary Figure 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
PDF File - 1091K, Schematic diagram illustrating the various analyses that were performed to estimate the accumulated amount of docetaxel in tumor tissue.
View article: Data from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Data from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
Purpose: Pharmacokinetics of docetaxel can be measured in vivo using positron emission tomography (PET) and a microdose of radiolabeled docetaxel ([11C]docetaxel). The objective of this study was to investigate whe…
View article: CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
View article: Supplementary Figure 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Supplementary Figure 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
PDF File - 1091K, Schematic diagram illustrating the various analyses that were performed to estimate the accumulated amount of docetaxel in tumor tissue.
View article: Supplementary Figure 1 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status
Supplementary Figure 1 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status Open
PDF file - 43K, Synthesis of 11Cerlotinib. Reaction conditions: 1.0 mg (2.6 μmole) of (1) 6-O-desmethyl-erlotinib, 11CCH3I, 250 μL of acetonitrile, 4.6 μmole of tetra-n-butylammonium hydroxide (2.0 μL of a 60% solution in water), 80 {degre…
View article: Supplementary Figure 2 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status
Supplementary Figure 2 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status Open
PDF file - 46K, Metabolite analysis. Mean fractions of parent 11Cerlotinib, nonpolar metabolites and polar metabolites for groups 1 (filled symbols) and 2 (open symbols). Vertical bars indicate standard deviations.
View article: Supplementary Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i>
Supplementary Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i> Open
Supplementary Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma In situ
View article: Data from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Data from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
Purpose: Pharmacokinetics of docetaxel can be measured in vivo using positron emission tomography (PET) and a microdose of radiolabeled docetaxel ([11C]docetaxel). The objective of this study was to investigate whe…
View article: Data from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status
Data from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status Open
Purpose: To evaluate whether, in patients with non–small cell lung carcinoma (NSCLC), tumor uptake of [11C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of trace…
View article: Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i>
Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i> Open
Background: Autofluorescence bronchoscopy is more sensitive than conventional bronchoscopy for detecting early airway mucosal lesions. Decreased specificity can lead to excessive biopsy and increased procedural time. Onco-LIFE, a de…
View article: Supplementary Figure 1 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status
Supplementary Figure 1 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status Open
PDF file - 43K, Synthesis of 11Cerlotinib. Reaction conditions: 1.0 mg (2.6 μmole) of (1) 6-O-desmethyl-erlotinib, 11CCH3I, 250 μL of acetonitrile, 4.6 μmole of tetra-n-butylammonium hydroxide (2.0 μL of a 60% solution in water), 80 {degre…
View article: Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i>
Data from Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i> Open
Background: Autofluorescence bronchoscopy is more sensitive than conventional bronchoscopy for detecting early airway mucosal lesions. Decreased specificity can lead to excessive biopsy and increased procedural time. Onco-LIFE, a de…
View article: Supplementary Table 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Supplementary Table 1 from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
PDF File - 77K, Supplementary data showing measurements in evaluable tumors.
View article: Supplementary Figure 2 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status
Supplementary Figure 2 from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status Open
PDF file - 46K, Metabolite analysis. Mean fractions of parent 11Cerlotinib, nonpolar metabolites and polar metabolites for groups 1 (filled symbols) and 2 (open symbols). Vertical bars indicate standard deviations.
View article: Data from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status
Data from Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status Open
Purpose: To evaluate whether, in patients with non–small cell lung carcinoma (NSCLC), tumor uptake of [11C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of trace…
View article: CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography Open
CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
View article: Familial multiple discoid fibromas is linked to a locus on chromosome 5 including the FNIP1 gene
Familial multiple discoid fibromas is linked to a locus on chromosome 5 including the FNIP1 gene Open
View article: Nintedanib for the Treatment of Symptomatic Radiation Pneumonitis. Case Report
Nintedanib for the Treatment of Symptomatic Radiation Pneumonitis. Case Report Open
View article: The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era
The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era Open
View article: Systematic review and meta‐analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage <scp>I–IIIA</scp> non‐small cell lung cancer
Systematic review and meta‐analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage <span>I–IIIA</span> non‐small cell lung cancer Open
Lymph node micrometastases could be one of the reasons for the high recurrence rate after complete surgical resection in stage I–IIIA non‐small cell lung cancer (NSCLC). The standard evaluation of a single haematoxylin and eosin (H&E) slid…
View article: Birt-Hogg-Dubé syndrome in apparent primary spontaneous pneumothorax patients; results and recommendations for clinical practice
Birt-Hogg-Dubé syndrome in apparent primary spontaneous pneumothorax patients; results and recommendations for clinical practice Open
View article: Development and validation of a supervised deep learning algorithm for automated whole‐slide programmed death‐ligand 1 tumour proportion score assessment in non‐small cell lung cancer
Development and validation of a supervised deep learning algorithm for automated whole‐slide programmed death‐ligand 1 tumour proportion score assessment in non‐small cell lung cancer Open
Aims Immunohistochemical programmed death‐ligand 1 (PD‐L1) staining to predict responsiveness to immunotherapy in patients with advanced non‐small cell lung cancer (NSCLC) has several drawbacks: a robust gold standard is lacking, and there…
View article: Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC Open
View article: High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases
High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases Open
CADM2 expression is up-regulated and closely associated with disease progression and poor prognosis in NSCLC patients with brain metastases. CADM2 expression warrants special consideration given its potential prognostic significance that m…
View article: nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+) Open
Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, f…